Renaissance Technologies LLC lifted its holdings in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 73.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,643,747 shares of the company's stock after acquiring an additional 694,012 shares during the period. Renaissance Technologies LLC owned approximately 2.87% of Black Diamond Therapeutics worth $3,501,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in BDTX. Vanguard Group Inc. increased its stake in Black Diamond Therapeutics by 4.1% in the third quarter. Vanguard Group Inc. now owns 2,188,857 shares of the company's stock valued at $8,296,000 after acquiring an additional 85,825 shares during the period. Dimensional Fund Advisors LP lifted its stake in Black Diamond Therapeutics by 51.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,301,664 shares of the company's stock worth $2,772,000 after purchasing an additional 444,649 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Black Diamond Therapeutics by 549.2% during the third quarter. Arrowstreet Capital Limited Partnership now owns 896,853 shares of the company's stock valued at $3,399,000 after purchasing an additional 758,709 shares in the last quarter. Marshall Wace LLP acquired a new stake in Black Diamond Therapeutics during the second quarter valued at approximately $1,830,000. Finally, UBS Group AG grew its stake in shares of Black Diamond Therapeutics by 100.3% in the 3rd quarter. UBS Group AG now owns 628,416 shares of the company's stock valued at $2,382,000 after purchasing an additional 314,716 shares during the period. 95.47% of the stock is currently owned by institutional investors and hedge funds.
Black Diamond Therapeutics Stock Performance
Shares of BDTX opened at $1.95 on Friday. The stock has a fifty day moving average price of $1.84 and a two-hundred day moving average price of $2.27. Black Diamond Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $4.94. The company has a market cap of $111.73 million, a price-to-earnings ratio of -2.60 and a beta of 3.28.
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. As a group, research analysts predict that Black Diamond Therapeutics, Inc. will post -0.6 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently commented on the company. Wall Street Zen lowered Black Diamond Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Weiss Ratings cut Black Diamond Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Monday, July 13th. HC Wainwright restated a "buy" rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. BTIG Research upped their target price on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, April 29th. Finally, TD Cowen reiterated a "buy" rating on shares of Black Diamond Therapeutics in a research report on Thursday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.83.
Check Out Our Latest Stock Report on Black Diamond Therapeutics
About Black Diamond Therapeutics
(
Free Report)
Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.
The company's development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.
See Also
Want to see what other hedge funds are holding BDTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
